Advertisement
Advertisement
U.S. Markets open in 7 hrs 57 mins
Advertisement
Advertisement
Advertisement
Advertisement

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4500-0.0700 (-1.99%)
At close: 04:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

    Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. “Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a vari

  • GlobeNewswire

    InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

    Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at sev

  • Benzinga

    InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder

    InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). The trial demonstrated a comparable clinical response of vilobelimab to the standard of care, significantly reducing the need for glucocorticoid (GC) treatment. Clinical response at week 16 in evaluable patients was observed in 16 out of 18 patients in the treatment group receiving vilobelimab alone; in 22 out of 23 patients receiving a standa

Advertisement
Advertisement